학술논문
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
Document Type
Article
Author
Source
In: Journal of Medical Economics . (Journal of Medical Economics, 2023, 26(1):1009-1018)
Subject
Language
English
ISSN
1941837X
13696998
13696998